Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming.

ABSTRACT:

Background

Chimeric antigen receptor T (CAR-T) cell therapy has been shown remarkable efficacy in the treatment of hematological malignancies in recent years. However, a considerable proportion of patients would experience tumor recurrence and deterioration. Insufficient CAR-T cell persistence is the major reason for relapse. Multiple strategies to enhance the long-term antitumor effects of CAR-T cells have been explored and developed. In this study, we focused on tyrosine kinase inhibitors (TKIs), which have emerged immunomodulatory potential besides direct tumoricidal effects.

Methods

Here, we screened 50 approved TKIs drugs and identified that afatinib (AFA) markedly enhanced the expressing of CD62L and inhibited reactive oxygen species level in T cells. And the underlyin

SUBMITTER: Dai Y 

PROVIDER: S-EPMC11574435 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature